​

Funding Round

Series A - Neurovance

Series A - Neurovance

Investment Firm

Overview

Neurovance is a clinical-stage neuroscience company that discovered and developed centanafadine (CTN) to help adults and children with ADHD.

Announced Date

Apr 03, 2014

Funding Type

Series A

Highlights

Location

United States, North America

Social

N/A

Investor Lead

N/A

Participant Investors

6

Investor Name
Participant InvestorTekla Capital Management
Participant InvestorVenture Investors
Participant InvestorState of Wisconsin Investment Board
Participant InvestorNovartis Venture Fund
Participant InvestorGBS Ventures

Round Details and Background

Neurovance raised $6300000 on 2014-04-03 in Series A

Neurovance is a clinical-stage neuroscience company that discovered and developed centanafadine (CTN) to help adults and children with ADHD.

Company Funding History

6

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Mar 26, 2015
Series A - Neurovance
-5.5M
Apr 03, 2014
Series A - Neurovance
7-6.3M
Oct 18, 2012
Venture Round - Neurovance
6-7.0M
Feb 03, 2012
Venture Round - Neurovance
-478.1K

Recent Activity

There is no recent news or activity for this profile.